Action NetraMark - PF0

NetraMark Holdings Inc (PF0) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

0,407

( 4,36% )

Prix Achat

0,456

Prix Vente

0,494

Volume échangé

1 500

0,407 Fourchette du Jour 0,407

0,00 Plage de 52 semaines 0,00

Clôture Veille

0,39

Ouverture

0,407

Dernière Transaction

1500

0.407

Dernière heure de transaction

21:14:26

Volume moyen (3 m)

Volume financier

VWAP

NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company

This agreement represents NetraMark's ninth commercial contract since the start of its current fiscal year and...

NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026

TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark Announces Change To Board Of Directors

TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI

TORONTO, May 04, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026

TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX:...

NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs

TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX:...

Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX:...

Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain

Publication strengthens NetraMark's case for biomarker-guided enrichment, individualized response modeling, and...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

PF0 - Frequently Asked Questions (FAQ)

What is the current NetraMark Holdings Inc share price?

The current share price of NetraMark Holdings Inc is 0,407 €

What is the 1 year trading range for NetraMark Holdings Inc share price?

NetraMark Holdings Inc has traded in the range of 0,00 € to 0,00 € during the past year

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

NetraMark Holdings Inc (PF0)

NetraMark Holdings Inc (PF0) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

PF0 Dernières nouvelles

NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company

NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026

NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting

NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum

NetraMark Announces Change To Board Of Directors

NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI

NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026

NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs

Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development

Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain

PF0 - Frequently Asked Questions (FAQ)

PF0 Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

NetraMark Holdings Inc (PF0)

NetraMark Holdings Inc (PF0) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

PF0 Dernières nouvelles

NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company

NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026

NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting

NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum

NetraMark Announces Change To Board Of Directors

NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI

NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026

NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs

Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development

Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain

PF0 - Frequently Asked Questions (FAQ)

PF0 Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE